The Hormone Refractory Prostate Cancer (HRPCA) Market is expected to witness substantial growth, with a projected compound annual growth rate (CAGR) of 8.9% in terms of value, reaching USD 17.05 Billion by 2027 from USD 8.56 Billion in 2019. HRPCA, also known as Castration-Resistant Prostate Cancer, is a type of prostate cancer that tends to recur after androgen deprivation therapy, and it has become increasingly relevant in the prostate cancer market.
https://www.reportsanddata.com..../report-detail/hormo
Like
Comment
Share
